NEW YORK, Sept. 07, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) will participate tomorrow (Monday)…
September 06, 2025 14:30 ET | Source: BridgeBio Pharma, Inc. - 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and…
SAN FRANCISCO, Sept. 06, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, Troper Wojcicki Philanthropies (TWP), and Lifebit today announced the…
After decades of outreach and evidence—never refuted—it is urgent to fund two 3D-CBS devices that could halve cancer deaths, and…
New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs1 BEERSE, BELGIUM ,…
TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a…
September 05, 2025 16:45 ET | Source: Helios Alliance Mobile, Alabama , Sept. 05, 2025 (GLOBE NEWSWIRE) -- Helios Alliance,…
September 05, 2025 09:55 ET | Source: Adagene Inc. SAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) --…
Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC) CHICAGO, Sept. 05, 2025 (GLOBE…
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~…